A cationic prodrug/therapeutic gene nanocomplex for the synergistic treatment of tumors

Biomaterials

Volumn 32, Issue 21, 2011, Pages 4849-4856

  Lu, Xiao ^a,b   Wang, Qing Qing ^a   Xu, Fu Jian ^b   Tang, Gu Ping ^a   Yang, Wan Tai ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

DNA; Doxorubicin; Gene therapy; Transfection; Vectors; Wild type p53

Indexed keywords

ANTI-TUMOR ACTIVITIES; BREAST CANCER CELLS; BREAST TUMOR; CANCER CELLS; CANCER THERAPY; CATIONIC POLYMERS; DOXORUBICIN; IN-VITRO; IN-VIVO; INHIBITION OF TUMOR GROWTH; MRNA EXPRESSION; NANOCOMPLEXES; PHYSICOCHEMICAL PROPERTY; POTENTIAL APPLICATIONS; PRODRUGS; RELEASE PROFILES; SURVIVAL TIME; THERAPEUTIC EFFECTS; THERAPEUTIC EFFICACY; TRANSFECTION; WESTERN BLOTS; WILD TYPES;

CELLS; CHEMOTHERAPY; DISEASES; DNA; GENE EXPRESSION; GENETIC ENGINEERING; PATIENT TREATMENT; TUMORS;

GENE THERAPY;

BETA CYCLODEXTRIN; BETA CYCLODEXTRIN POLYETHYLENIMINE DOXORUBICIN COJUGATE; DOXORUBICIN; MESSENGER RNA; PLASMID DNA; PLASMID VECTOR; POLYETHYLENEIMINE; PRODRUG; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; COMPLEX FORMATION; CONTROLLED STUDY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SURVIVAL TIME; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CATIONS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, P53; HUMANS; MATERIALS TESTING; MICE; MICE, NUDE; NANOSTRUCTURES; PRODRUGS;

MUS;

EID: 79955764204     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.03.022     Document Type: Article

References (34)

1. Vauthier C., Couvreur P. Nanomedicines: a new approach for the treatment of serious diseases. J Biomed Nanotechnol 2007, 3:223-234.
2. Xu F.G., Ma Q.Y., Sha H.C. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment. Crit Rev Ther Drug Carrier Syst 2007, 24:445-492.
3. Raffa V., Vittorio O., Riggio C., Cuschieri A. Progress in nanotechnology for healthcare. Minim Invasive Ther Allied Technol 2010, 19:127-135.
4. Aulenta F., Hayes W., Rannard S. Dendrimers: a new class of nanoscopic containers and delivery devices. Eur Polym J 2003, 39:1741-1771.
5. Satchi-Fainaro R., Duncan R., Barnes C.M. Polymer therapeutics for cancer: current status and future challenges. Adv Polym Sci 2006, 193:1-65.
6. Vicent M.J. Polymer-drug conjugates as modulators of cellular apoptosis. AAPS J 2007, 9:E200-E207.
7. Tong R., Cheng J.J. Anticancer polymeric nanomedicines. Polym Rev 2007, 47:345-381.
8. Marchisone C., Pfeffer U., Del Grosso F., Noonan D.M., Santi L., Albini A. Progress towards gene therapy for cancer. J Exp Clin Cancer Res 2000, 19:261-270.
9. Martini A., Ciocca C. Drug delivery systems for cancer drugs. Expert Opin Ther Pat 2003, 13:1801-1807.
10. Reddy L.H. Drug delivery to tumours: recent strategies. J Pharm Pharmacol 2005, 57:1231-1242.
11. Keane M.M., Ettenberg S.A., Nau M.M., Russell E.K., Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999, 59:734-741.
12. Singh T.R., Shankar S., Chen W.F., Asim M., Srivastava R.K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003, 63:5390-5400.
13. Juliger S., Goenaga-Infante H., Lister T.A., Fitzgibbon J., Joel S.P. Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappa B inhibition and the rapid generation of other selenium species. Cancer Res 2007, 67:10984-10992.
14. Hastak K., Alli E., Ford J.M. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010, 70:7970-7980.
15. Lowe S.W., Bodis S., Mcclatchey A., Remington L., Ruley H.E., Fisher D.E., et al. P53 status and the efficacy of cancer-therapy in-vivo. Science 1994, 266:807-810.
16. Levine A.J., Momand J. Tumor suppressor genes-the P53 and retinoblastoma sensitivity genes and gene-products. Biochim Biophys Acta 1990, 1032:119-136.
17. Michalovitz D., Halevy O., Oren M. P53 mutations-gains or losses. J Cell Biochem 1991, 45:22-29.
18. Lane D.P., Benchimol S. P53-oncogene or anti-oncogene. Genes Dev 1990, 4:1-8.
19. Fornari F.A., Randolph J.K., Yalowich J.C., Ritke M.K., Gewirtz D.A. Interference by doxorubicin with DNA unwinding in Mcf-7 breast-tumor cells. Mol Pharmacol 1994, 45:649-656.
20. Fornari F.A., Jarvis W.D., Grant S., Orr M.S., Randolph J.K., White F.K.H., et al. Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem Pharmacol 1996, 51:931-940.
21. Wang Y., Gao S.J., Ye W.H., Yoon H.S., Yang Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5:791-796.
22. Wiradharma N., Tong Y.W., Yang Y.Y. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials 2009, 30:3100-3109.
23. Huang H.L., Yu H., Tang G.P., Wang Q.Q., Li J. Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. Biomaterials 2010, 31:1830-1838.
24. Yao H., Ng S.S., Tucker W.O., Tsang Y.K.T., Man K., Wang X.M., et al. The gene transfection efficiency of a folate-PEI600-cyclodextrin nanopolymer. Biomaterials 2009, 30:5793-5803.
25. Huang H.L., Yu H., Li D., Liu Y., Shen F., Zhou J., et al. A novel co-polymer based on hydroxypropyl alpha-cyclodextrin conjugated to low molecular weight polyethylenimine as an in vitro gene delivery vector. Int J Mol Sci 2008, 9:2278-2289.
26. Zhang W., Chen Z., Song X.X., Si J.M., Tang G.P. Low generation polypropylenimine dendrimer graft beta-cyclodextrin: an efficient vector for gene delivery system. Tech Canc Res Treat 2008, 7:103-108.
27. Tang G.P., Guo H.Y., Alexis F., Wang X., Zeng S., Lim T.M., et al. Low molecular weight polyethylenimines linked by beta-cyclodextrin for gene transfer into the nervous system. J Gene Med 2006, 8:736-744.
28. Huang H.L., Tang G.P., Wang Q.Q., Li D., Shen F.P., Zhou J., et al. Two novel non-viral gene delivery vectors: low molecular weight polyethylenimine cross-linked by (2-hydroxypropyl)-beta-cyclodextrin or (2-hydroxypropyl)-gamma-cyclodextrin. Chem Commun 2006, 2382-2384.
29. Liu S., Wiradharma N., Gao S., Tong Y., Yang Y.Y. Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs. Biomaterials 2007, 28:1423-1433.
30. Troester M.A., Herschkowitz J.I., Oh D.S., He X.P., Hoadley K.A., Barbier C.S., et al. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006, 6:276.
31. Yang X.H., Sladek T.L., Liu X.S., Butler B.R., Froelich C.J., Thor A.D. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 2001, 61:348-354.
32. Engel D., Nudelman A., Levovich I., Gruss-Fischer T., Entin-Meer M., Phillips D.R., et al. Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines. J Cancer Res Clin 2006, 132:673-683.
33. Katayose Y., Kim M., Rakkar A.N.S., Li Z.W., Cowan K.H., Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997, 57:5441-5445.
34. Santos D.L., Moreno A.J.M., Leino R.L., Froberg M.K., Wallace K.B. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 2002, 185:218-227.